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 Detection of lipids and lipid/cyclodextrin complexes is a nontrivial aspect in 
novel treatments of Niemann-Pick disease type C.  Recently, the FDA approved 
Hydroxypropyl-β-cyclodextrin as a treatment for the condition, as it had shown 
promising results in mice in the removal of neurodegeneration biomarkers.1  Several 
lipids of concern in Niemann-Pick disease type C, and their corresponding cyclodextrin 
complexes were detected via traveling-wave ion mobility mass spectrometry (T-Wave-
MS).  In addition to detection alone by MS, collision cross sections (CCS) of the ions 
were measured within the T-Wave cell, to give insight as to the size of the complexes.  
As shown, using cyclodextrins to complex lipids shifts their place within the m/z vs. CCS 
space, aiding the spectral interpretation process for detecting the complexes. 
 Additionally, a study of how wave height within the T-Wave cell effects the CCSs 
obtained was performed.  Here, evidence for dipole alignment within the T-Wave cell is 








Recently, the FDA approved Hydroxypropyl-Beta-Cyclodextrin as a treatment for 
Niemann-Picks Disease Type C (NPC).1a NPC is a relatively rare genetic disorder 
involving the NPC1 and NPC2 gene that affects 1:150,000 people of western European 
ancestry.2  Of the two genes, mutations in the NPC2 gene account for only about 4% of 
cases; previously this was given the title “Niemann-Picks disease type D,” however it is 
now recognized as the same condition.2  The disease affects lipid storage in the body, 
specifically the intracellular movement of lipids, like glycosphingolipids, and 
cholesterol.1b, 2  This results in several fatal conditions such as ascites, ataxia, and 
respiratory failure.2  Onset may occur at any age, and can result in developmental issues 
in infants and children.2  Due to this newfound use as a treatment for NPC, cyclodextrin 
molecules have become particularly significant to the pharmaceutical industry.1a, 3  
Cyclodextrin molecules are cyclic compounds composed of 6-8 glucopyranoside 
monomers bound in a conical fashion (named alpha- beta-, and gamma-cyclodextrin 
respectively).  The monomers’ unique orientation produces a hydrophilic outer shell and 
a hydrophobic inner shell, whose inner radius is 0.57 nm, 0.78 nm, and 0.95 nm for 
alpha-, beta-, and gamma-cyclodextrin, respectively.4  Hydrophobic moieties (CH2-, etc.) 
comprise the interior of the structures, while the outside holds the hydrophilic functional 
groups of the glucose monomers (-OH).  This structure allows cyclodextrin rings the 
unique ability to act as a “host” to “guest” hydrophobic molecules by forming non-
 2 
covalent inclusion complexes; this in turn increases the solubility of hydrophobic 
molecules in aqueous solution.3   
The formation of guest-host complexes in solution have significant implications 
in treating lipid-related diseases and drug delivery.1a, 5 Cyclodextrin guest-host complexes 
have been identified with several classes of molecules, including aromatics, barbiturates, 
and dicarboxylic acids in both negative and positive ion mode mass spectrometry (MS).6  
Several tools, such as UV-visible spectroscopy, NMR, and mass spectrometry can used to 
determine the orientation and stoichiometry for such complexes.6b, 7 As, noted by Tabushi 
et al. the guest-host complexes are mostly driven by van der Waal interactions, however 
the conformational energy of cyclodextrin, and the collapse of water clusters are 
important thermodynamic factors as well.8  Still, cyclodextrin-lipid complexes have not 
yet been studied in detail, despite their emerging use as new drugs for treating lipid 
storage metabolic disorders.   
This project aims to determine the collision cross sections (CCS) of several 
cyclodextrin molecules, and cyclodextrin-lipid complexes via traveling wave ion mobility 
(T-wave) measurements. CCS values represent the conformational structures of 
molecules in the gas phase; however these measurements are dependent on the gas used 
to collide with the molecule of interest.  E.W. McDaniel at Georgia Institute of 
Technology invented ion mobility spectrometry in the 1950’s and 60’s.9 Since then 
several variants of the original technique have been employed and commercialized, 
including the traveling-wave ion mobility spectrometer (T-Wave).   
T-wave is a relatively new form of ion mobility spectrometry (IMS), which has 
become popular in the MS community due to its commercial availability in the Waters 
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Synapt G2 HDMS system.9b, 10  The instrument functions by pulsing an electric potential 
wave in the same direction as an ion beam passing through a “drift region.” In opposition 
to the ion beam is a low pressure inert gas (usually Helium or Nitrogen on the order of 1-
5 torr), called a “drift gas”.10b  Collisions with the drift gas will slow ions, and therefore 
the ions will have a longer drift time through the T-Wave cell.  Thus, ions are separated 
by their CCSs, as ions with larger CCSs will have more collisions with the drift gas.  
Guest-host interactions, similar to those shown here, have proven beneficial in ion 
mobility spectrometric (IMS) separations.11 Because guest-host complexes have a 
different CCS value than the naked guest, the host shifts the drift time of the guest in the 
IMS dimension.  Therefore, these guest-host interactions can aid in separating molecules 
of interest from a potentially complex matrix.  Additionally, guests can be removed from 
their hosts via collisional-induced dissociation (CID) to do the weak van der Waals forces 
holding the complex together.11 This allows for separation of guest-host complexes from 
complex solutions, followed by detection of the naked guest by MS/MS. 
 The main advantage IMS has over other separation techniques is its ability to 
rapidly separate molecules of different sizes. Where chromatographic techniques may 
require a tens of minutes to a an hour for a complete separation, IMS separations occur in  
milliseconds. In addition, it has been shown that coupling IMS separations prior to mass 
analysis increases the peak capacity of an experiment.11a, 12 IM-MS separations 
employing a shift reagent have recently been shown to increase peak capacity to 
approximately 2400; nearly twice the reported peak capacity of IM-MS experiments 
performed without a shift reagent.11c 
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 Despite the high-throughput capabilities of IMS, the technique does have a few 
drawbacks.  T-wave, in particular suffers from low resolution (due to the drift cell being 
at a reduced pressure), and mobility-dependent resolution; drift tube ion mobility 
spectrometry, however does have much improved resolution compared to T-Wave.10b  In 
addition to T-wave’s low resolution the separation is not completely orthogonal to mass 
analysis, by which it is usually accompanied.11c The ion’s flight down the drift tube is 
determined by two related factors: its CCS value and its mass to charge ratio (m/z).  
Thus, IM-MS analysis does not exploit the m/z vs. CCS space to its full extent.  Still, as 
we demonstrate here, IMS is a powerful, convenient, and fast technique for separating 
gas-phase ions prior to mass analysis. 
In the early stages of development of T-wave separations, there was a lack of a 
standard procedure for calibrating the T-wave drift times to obtain CCS values due to a 
lack of theoretical understanding of how the separation inside the drift cell occurred; 
nevertheless, work leading to a new calibration method was published in 2004.13  Since 
then, more advanced theory and calibration methodologies for T-wave IMS have been 
developed.10b, 14 The calibration method Ruotolo published in 2008 is employed in this 
work.14a  This calibration external standard, which is then used to construct a calibration 
curve, allowing for drift times obtained experimentally to be used to calculate CCS 
values.  
To date, T-wave has been shown to give accurate and precise CCS values of 
biologically relevant species that match those from previously established techniques like 
x-ray crystallography and NMR within 2% error.10a In addition, studies have shown that 
gas-phase proteins retain their aqueous-phase densities within the ion mobility drift tube; 
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this is significant because it shows that conclusions drawn about molecular structures 
from ion mobility studies not only match other techniques, but also reflect solution 
conformations within biological systems.14b   
The work presented here demonstrates fundamental aspects of T-wave-MS and its 
application of biological systems.  First, T-wave was used to reveal the structural 
diversity of ESI-formed clusters of various cyclodextrins and calculate their CCS values.  
Several cyclodextrin-lipid complexes were also studied in this manner.  Additionally, the 
effect of the traveling wave electric field magnitude (wave height) on the calculated CCS 
value was determined. This study provides new insights on the complexation of lipids in 
cyclodextrin-containing solutions, as well as the limits of the analytical instruments used 
to examine them. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
All lipids used were purchased from Avanti Polar Lipids (Alabaster, Alabama).  
Lipids were stored at -80˚C prior to being opened.  Once opened, lipids were dissolved in 
1:1:1 MeOH:H2O:AcN and refrigerated.  Cyclodextrins were purchased from TCI 
America (Portland, OR) and stored at room temperature.  Cholesterol and Polyalanine 
were purchased from Sigma Aldrich (St. Louis, MO). Solvents used were purchased from 
EMD.  All materials were used without further purification.   
Solutions of cyclodextrin molecules, cyclodextrin-lipid complexes, and 
polyalanine were dissolved in a solution of 50/50 (v/v) methanol/water. Cholesterol was 
dissolved in 2:1 methanol/chloroform (v/v), and experiments containing both cholesterol 
and HP-βCD were also dissolved in 2:1 methanol/chloroform (v/v).  For T-wave 
calibration, a solution of polyalanine was used at a concentration of approximately 33 
nM. 
 For T-wave-MS experiments, a Waters SYNAPT G2 ion mobility mass 
spectrometer was used.  The instrument is equipped with an electrospray ionization 
source (ESI) held at 4.0 kV for positive mode and -2.8 kV for negative mode with a 
sample solution flow rate of 25 µL/min. Following ionization, the ions are guided to a 
quadrupole mass filter, and into the T-wave.  After IMS separation, the ions are pushed 
into an orthogonal acceleration time-of-flight mass analyzer equipped with a reflectron 
(oa-reToF). The instrument specifics are further outlined elsewhere.15  The T-wave drift 
cell was set to a wave height of 30 V and velocity of 300 m/s unless otherwise noted.  
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Nitrogen was used as the drift gas throughout the experiments. Nitrogen was purchased 





The calibration method employed here was first outlined by Ruotolo, as mentioned 
earlier.14a  Briefly, CCS values are traditionally determined via drift-tube IMS 






















where Ω is the CCS value.  This value is then made mass and charge independent (Ω’), 















where A and B are experimentally determined using an external calibrant.   
 In all CCS calculations a solution of polyalanine was used as the CCS calibrant 
using values from Dr. Clemmer’s database at Indiana University.16  It is recognized that 
using polyalanine as a calibrant for cyclodextrin is not ideal due to the molecules’ 
different structural attributes.14b  However given Dr. Clemmer’s extensive database 
regarding polyalanine and a lack of molecules similar to cyclodextrin’s structure and size 





Positive mode investigation of cyclodextrins 
Alpha-, beta-, and gamma-cyclodextrins expectedly had similar spectra, as the 
only difference between the three compounds is the number of glucose monomers within 
the oligosaccharide (six, seven, and eight monomers respectively).  For all three 
compounds, the most intense signal was the [M+K+H]2+ adduct.  Likewise, in the 1+ 
charge state trend line the most intense peak comes from the [M+Na]+ adduct, the 2+ 
charge state’s most intense peak was the [M+K+H]2+ , and the triply charged charge 
states most intense peak was a result of the [4M+2K+H]3+ adduct.   
Amino-beta-cyclodextrin had slightly different spectra than the unfunctionalized 
cyclodextrins.  The most intense peak in the IM-MS spectrum is from the 1+ in 
opposition to the unfunctionalized spectra; the peak is the [M+H]+.  Clearly this change 
is due to the basic nature of the amino moiety added to the cyclodextrin.  The most 
intense peak in the 2+ charge state follows true to it’s unfunctionalized counterparts as 
[M+K+H]2+, however the 3+ charge state deviates from the trend set with alpha-, beta-, 
and gamma-cyclodextrin again.  The most intense peak in this spectrum was the 
[6M+3H]3+.  Again, the amino moiety is showing a preference for protonation over 
adduction with alkali ions. 
Hydroxypropyl-beta-cyclodextrin showed almost exclusively the 2+ charge state.  
The 1+ and 3+ charge states were too weak to be able to definitely assign the peaks.  
The 2+ charge state however clearly showed both the [M+K+H]2+ and [2M+K+H]2+ ions 




Negative Mode investigation of Cyclodextrins 
 Both alpha and beta cyclodextrin had their most abundant species as [M-H]1-, 
however gamma’s most intense peak was the doubly charged dimer, [2M-2H]2-.  For the 
doubly charged anionic state, beta and gamma cyclodextrin shared the same [2M-2H]2- 
base peak, while alpha-cyclodextrin’s base peak was [3M-2H]2-.  The triply charged state 
however, was different for each cyclodextrin, as indicated in Figures 6-8. 
 Amino-beta-cyclodextrin was more similar to the unfunctionalized cyclodextrins 
in negative mode than positive mode.  As indicated by Figure 9 the base peak for the 
spectrum was [M-H]1-.  For the 2- charge state the base peak was [2M-2H]2-, and for the 
triply charged 3- state the base peak was [5M-3H]3-.   
 Hydroxypropyl-beta-cyclodextrin showed a very different range of charge states 
than those observed in positive mode.  Both the 1-, and the 2- had identifiable peaks, 
although the triply charged state, again, did not have identifiable peaks.  The base peak of 
the spectrum was [M-H]1- and the base peak of the 2- charge state was [2M+K+Na-4H]2-. 
 
Lipid/alpha-cyclodextrin non-covalent inclusion complexes 
 In these experiments three lipid/alpha-cyclodextrin non-covalent inclusion 
complexes were investigated.  The lipids tested were sphinganine, sphingosine, and four 
phosphatidylcholines, of which only one complex with alpha-cyclodextrin was 
successfully detected.  
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 Sphinganine was detected as [M+H]+ with a drift time of 3.80ms through the T-
Wave cell.  The sphinganine complex was detected as [M+αCD+H]+ with a drift time of 
7.95ms.   
 Similarly, sphingosine was detected as its [M+H]+ ion with a drift time of 3.88ms.  
The sphingosine complex with alpha-cyclodextrin was detected at 8.09ms, and thus a 
shift in drift time of 4.21ms as the monomeric [M+αCD+H]+.   
 The final complex investigated was with 1-Palmitoyl-2-Myristoyl-sn-Gylcero-3-
phosphocholine (PMG).  The phosphocholine was detect at 7.95ms as the [M+H]+ ion.  
The complex with alpha-cyclodextrin was detected as a doubly charged species, and thus 
as a substantially short drift time than the lipid alone, as opposed to the other lipids 
whose complex drifted slower through the T-wave cell than the uncomplexed lipid; the 
complex was detected at 2.37ms, as the [M+αCD+H+K]2+ adduct. 
 
Cholesterol/hydroxypropyl-beta-cyclodextrin inclusion complex 
 HP-βCD and cholesterol were added to a solution of 2:1 methanol/chloroform.  
Detection of a complex between the two was unsuccessful, despite its prescience in prior 
literature.17  Still, dehydrated cholesterol was detected at m/z 369.3621.  At a wave height 
of 30V, dehydrated cholesterol’s drift time was 1.75ms; this corresponds to a CCS of 
134Å2. 
  
Effect of wave height on CCS Values 
 In addition to the experiments involving cyclodextrins as shift reagents, wave 
heights of the travelling wave applied to the drift cell were varied to determine the effect 
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on CCS values.  As shown in Table 11 the height of the electric field wave can 
dramatically affect the calculated CCS value of not only lipids, but complexes as well.  
This is demonstrated by the ratio of 40V CCS over 25V CCS the lipids and complexes 
underwent as the wave height was increased.  The PMG ion changed the least by 
increasing by a ratio of 1.06, whereas the PMG complex changed the most by decreasing 
by a ratio of 0.44.  Additionally, a wave height of 25 V, a CCS of 134 Å2 for sphingosine, 
223 Å2 for the complex with alpha-cyclodextrin were obtained, while at 40 V sphingosine 
showed a CCS value of 143 Å2, and its complex 187Å2. These changes in CCS with wave 






Positive mode investigation of cyclodextrins 
Five cyclodextrin molecules were investigated by ESI as their different charge 
states, and adducts were separated by T-Wave IMS and detected by MS.  All of the 
spectra were very complex due to various alkali adducts at each charge state, but the IM 
stage aided in spectral investigation.  Identified species are shown in Tables 1-10.  Each 
line going from the origin in the bottom right and leading to and to the right indicates a 
different charge state family, unfolding to a spectrum that coincidently resembles a “fan” 
surrounding the [3nM+nAlkali]n+ vertical line (approximately at 3000m/z for the alpha-
cyclodextrin spectrum), where n is a whole number.  As seen from this trend, lines 
corresponding up to 8+ charge states seem to have been faintly detected, however the 
adducts corresponding to these peaks are too weak to be correctly identified in the MS 
spectrum.   Thus, because charge states 4+ and higher are not resolvable, only charge 
states 1+ though 3+ are discusses herein; in negative mode charge state 4- and higher are 
not resolvable, thus like positive mode, only charge states 1- through 3- will be discussed. 
Of the data obtained, CCS values were not directly correlated to the mass of the 
adduct.  For instance, the [M+Na]+ ion was substantially larger than the [M+K+H]2+ ion 
in the unfunctionalized CD’s and in Amino-βCD; the singly charged ion is larger by at 
least 30 Å2 in all cases, and as high as 82 Å2 in the case of αCD.  The explanation of this 
observation depends on where the charges lie in space.  If the two charges were close to 
each other, a strong dipole could align with the electric field causing a smaller CCS with 
the drift gas.18  Dipole alignment is a phenomenon where the ion’s dipole aligns with the 
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electric field in the T-Wave cell, if the electric field can do enough work on the ion to 
overcome the rotational energy of the ion.18  Depending on the direction of the ion’s 
dipole, the ion may lie either more parallel or perpendicular to the drift region, giving 
either a smaller or larger CCS value, respectively.18  However, if the charges were too 
close to each other, Coulombic repulsion would cause the ion to expand and result in a 
larger CCS.  Thus, the charges must be moderately distant from each other in order to 
maximize the ions dipole with minimal Coulombic repulsion to have the ion’s dipole 
align with the T-Wave electric field and result in a smaller CCS. Molecular dynamic 
calculations to determine the placement of charges on the ions have not been performed. 
Additionally, the CCS of the [4M+2K+H]3+ complexes was only about twice the 
size of any of the monomer adducts in the α, β , and γCD spectra.  These unexpected 
trends in the CCS of the ions again point to dipole alignment within the T-Wave cell.  
HP-βCD had a very different spectrum than the other cyclodextrins, mainly 
because of when βCD is functionalized to HP-βCD.  The functionalization replaces a 
hydroxyl group with a 2-hydroxypropyl group; additional functionalization may occur at 
the hydroxyl on the 2-hydroxypropyl resulting in a polymerization of 2-hydroxypropyl 
moieties on cyclodextrin.17 The process is non-regioselective instead of a simple, single 
substitution, so HP-βCD appears as several polymeric envelopes in its spectra (the base 
peak in the 2+ spectrum was the result of the addition of seven 2-hydroxypropyl groups).   
Aside from this feature, the most peculiar part to the spectrum was the extreme 
intensity of the doubly charged state compared to the 1+ and 3+ states.  The 2+ charge 
state was about 100 times more intense than that of the 1+ state, and 3+ was so weak that 
resolution suffered and peaks could not be assigned. As a comparison, in all the other 
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spectra the 2+ and 1+ states were at least within an order of magnitude to each other, and 
the 2+ and 3+ were within 2 orders of magnitude to each other.  A theoretical explanation 
for this observation may be attainable through molecular dynamic simulations, however 
these have not been performed.  However, it is clear that this HP-βCD is more stable as a 
2+ cation than any of the other CDs investigated here. 
 
Negative Mode investigation of Cyclodextrins 
 In negative mode, CCS values were not obtained, as the polyalanine T-Wave 
calibrant did not ionize effectively using negative mode ESI.  Additionally, the spectra in 
negative mode were generally less intense than their positive mode analogues.   
 For the unfunctionalized CD’s and Amino-βCD the negative mode spectra were 
relatively predictable, and thus they will not be discussed in depth.  It was interesting that 
alkali cation contaminates complicated the negative mode spectra as well.  The only 
anion that adducted with the CDs was chloride, and all other negative charges 
accumulated were from the loss of a hydroxyl proton.  Additionally, no adduct was 
identified with both halogen anions, and alkali metal cations; all were either halide 
adducts, or alkali adducts with the loss of one to several protons. 
 HP-βCD again had a complex spectrum compared to the other CD’s due to its 
functionalization process.  In negative mode the 1- charge state was about an order of 





Lipid/alpha-cyclodextrin non-covalent inclusion complexes 
 In addition to spectra of various cyclodextrins, several lipids were successfully 
complexed and ionized.  Sphinganine and sphingosine are sphingolipids typically found 
in brain tissue, and their glycosylated counterparts are of specific interest in NPC.1b  As 
shown in Figures 11-12, the addition of cyclodextrin greatly changes the spectrum.  The 
complexes have very different drift times as compared to the naked lipids, and both were 
detected as a singly charged ion.  Because of the complex formation, the two lipids had 
similar cross sections (223 and 225 Å2 respectively), and thus like their naked ions, the 
complexes would be very difficult to resolve in the IMS spectrum alone.  
 The other lipid successfully detected as a CD non-covalent complex, PMG, is a 
phosphatidylcholine. This was detected as a doubly charged ion, and because of this the 
complexes drift time was shorter than the naked ion, unlike the sphingolipids.  The 
additional charge on the phosphatidylcholine complex is likely on the lipid itself.  The 
lipid is zwitterionic, with a cationic quaternary amine and an anionic phosphate moiety.  
The additional charge is likely on the phosphate group, neutralizing the moiety and 
making the net charge of the ion 1+.  Because the two classes of lipids were shifted in 
opposite directions in the IM spectrum, this may mean that different class of lipids may 
be able to be separated using a single cyclodextrin. In order for this to be the case, all 
lipids of the same class would have to ionize to the same charge state. However, more 
lipid complexes would need to be detected to draw a definitive conclusion.   
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Cholesterol/hydroxypropyl-beta-cyclodextrin inclusion complex 
 As noted before, a complex between cholesterol and HP-βCD was not detected.   
This is most likely due to the complex dissociating during the ESI process, as the 
complex has been detected using a multimode electrospray ionization/ atmospheric 
pressure photoionization (ESPI) source.17  Experiments in an effort to detect the complex 
used a capillary voltage as low as 2kV in order to avoid dissociation were also 
unsuccessful.  Therefore, the van der Waal forces holding the cholesterol within the 
cyclodextrin must be significantly weaker than the forces holding the other complexes 
reported here together, as those complexes were detected using a capillary voltage of 
4kV.  Additionally, the previously reported detection of the complex used very high 
concentrations (1mM), whereas in the experiments preformed here were using 
concentrations of 60µM cholesterol and 250µM HP- βCD. 
 Still, cholesterol was successfully ionized by ESI with minimal fragmentation.  
Cholesterol was observed as [M-H2O+H]+, and had a CCS of 134 at 30V wave height.  
 
Effect of wave height on CCS Calculations 
 In addition to the previous survey experiments, the effect of the height of the 
travelling wave on the conformation of several ions and complexes was studied in order 
to examine changes in the corresponding CCS values.  In addition to the lipids and 
complexes tested, leucine-enkephalin (Leu-Enk) was tested as well.  This was done as a 
way to ensure our calibration produced CCS values that matched literature results.  The 
data obtained from these experiments show Leu-enk had a CCS of 126Å2 at 25 V wave 
height, with previous reports indicating anywhere from 150Å2 to 400Å2 through 
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computational models, although a value of 162Å2 was reported via IMS.19  The ESI 
needle was held at 4krV, and thus the protein could have unfolded during ionization 
leading to a smaller CCS.  Additionally, the computational methods employed to 
calculate the CCS may have been performed assuming a different drift gas, or in some 
cases, were extrapolated from data of other proteins like bradykinin.19c, 19e  
 The trend throughout the data is that naked lipids increase in CCS as wave height 
increases, however than their complexed analogues decrease in CCS as wave height is 
increase.  This is likely due to the rigidity associated with the complexation.  Because the 
hydrocarbon chain on the lipids is inserted in the cyclodextrin ring, the chains have fewer 
conformations available to them, and are therefore more rigid than their naked 
counterparts.  This gives the ion a more definite shape, and ultimately this manifests itself 
into an observable dipole alignment, as shown by the various CCS values in Table 11.   
 The naked ions, without the added rigidity of the cyclodextrin host, have many 
more conformations available to them.  Therefore, the hydrocarbon chain is allowed to 
rotate, and rapidly change conformation; furthermore, the internal energy of the ion 
would increase within a higher electric field allowing higher energy rotational state to be 
reached.  These changes would be centered on the charged head group, and therefore the 
ion would not have a definite dipole, unlike the complexes.  Thus dipole alignment is not 
observed. Instead, there is much less variation in CCS values, shown by the smaller 
deviations of the naked ions compared to the complexes.   
 Like the cyclodextrin complexes, dipole alignment was also observable with 
cholesterol at high wave heights.  Cholesterol was the only naked ion observed to 
decrease in CCS as wave height was increased.  Unlike other naked ions, cholesterol has 
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a rigid polycyclic hydrocarbon structure.  This rigidity leads to a fixed dipole on the ion, 
which then could align with the electric field in the T-Wave cell.  As wave height was 
varied from 25V to 35V the CCS only changed by 2Å2 (from 136Å2 to 134Å2 
respectively).  However at 40V a significant change in CCS was observed.  The CCS 
decreased to 104Å2 at 40V, which again is likely due to dipole alignment within the T-






 Non-covalent inclusion complexes are growing in importance in the 
pharmaceutical industry as drug delivery agents.  In particular, hydroxypropyl-β-
cyclodextrin is new approval as a treatment for Niemann-Pick type C has made the 
detection of lipids and lipid/cyclodextrin complexes nontrivial.  In the data presented, 
detection of these complexes was accomplished via T-Wave-MS; in addition to this CCS 
values were obtained by the ions corresponding drift time through the T-Wave cell.  As 
shown in Figures 11-13, complexation of the lipids with cyclodextrin shifts their point in 
the m/z vs. CCS space, which can aid in their detection and spectral interpretation. 
 In addition, to these findings, evidence of dipole alignment within the T-Wave 
cell was found.  As shown in Table 11, more rigid ions, which would have a fixed dipole, 
decrease in CCS as wave height is increased; the ratio of CCS at 40V to 25V for these 
ions was between 0.44 to 0.84.  In contrast to this, ions with freer rotations had larger 
CCS values at increased wave heights, although this increase was less pronounced than 
the decrease seen in rigid ions.  This is likely due to increased internal energy of the ions 
at higher wave heights, leading to more energetic rotations of the hydrocarbon chain and 
ultimately a larger CCS. 
 A complex between cholesterol and HP-βCD was not detected, although 
dehydrated cholesterol ions were.  Therefore, CCS for dehydrated cholesterol were 
obtained, and subjected to various wave heights within the T-Wave.  Again, like the rigid 
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lipid/cyclodextrin complexes, smaller CCS values were obtained for cholesterol at higher 
wave heights. 
 Ion mobility spectrometry is a rapid separations technique increasing in popularity 
within the MS community.  The experiments presented here demonstrate both 
fundamental aspects of traveling-wave ion mobility mass spectrometry, as well as its 
applications to biomolecules. As shown, the introduction of shift reagents can aid in 
spectral interpretations of the complex two-dimensional data.  In addition to this, 
parameters within the T-Wave can greatly affect the CCSs obtained, and should be set 




Figure 1: A) IM-MS Spectrum of α-Cyclodextrin. B) MS Spectrum of α-Cyclodextrin; 
Base Peak [M+K+H]2+ CCS: 145 Å2. C) Charge State 1+ from IM-MS Spectrum of α-
Cyclodextrin; Base Peak [M+Na]+ CCS: 227 Å2 (* m/z=301=[Dibutylphthalate +Na]+). 
D) Charge State 2+ from IM-MS Spectrum of α-Cyclodextrin; Base Peak [M+K+H]2+ 
CCS: 145 Å2. E) Charge State 3+ from IM-MS Spectrum of α-Cyclodextrin; Base Peak 
[4M+2K+H]3+ CCS: 503 Å2. 
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Figure 2: A) IM-MS Spectrum of β-Cyclodextrin. B) MS Spectrum of β-Cyclodextrin; 
Base Peak [M+K+H]2+ CCS: 202 Å2. C) Charge State 1+ from IM-MS Spectrum of β-
Cyclodextrin; Base Peak [M+Na]+ CCS: 255 Å2. D) Charge State 2+ from IM-MS 
Spectrum of β-Cyclodextrin; Base Peak [M+K+H]2+ CCS: 202 Å2. E) Charge State 3+ 
from IM-MS Spectrum of β-Cyclodextrin; Base Peak [4M+2K+H]3+ CCS: 575#Å2. 
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Figure 3: A) IM-MS Spectrum of ɣ-Cyclodextrin. B) MS Spectrum of ɣ-Cyclodextrin; 
Base Peak [M+K+H]2+ CCS: 230 Å2. C) Charge State 1+ from IM-MS Spectrum of ɣ-
Cyclodextrin; Base Peak [M+Na]+ CCS: 260 Å2. D) Charge State 2+ from IM-MS 
Spectrum of ɣ-Cyclodextrin; Base Peak [M+K+H]2+ CCS: 230 Å2.  E) Charge State 3+ 
from IM-MS Spectrum of ɣ-Cyclodextrin; Base Peak [4M+2K+H]3+ CCS: 607 Å2. 
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Figure 4: A) IM-MS Spectrum of Amino-β -Cyclodextrin. B) MS Spectrum of Amino-β -
Cyclodextrin; Base Peak [M+H]+ CCS: 252 Å2. C) Charge State 1+ from IM-MS 
Spectrum of Amino-β -Cyclodextrin; Base Peak [M+H]+ CCS: 252 Å2. D) Charge State 
2+ from IM-MS Spectrum of Amino-β -Cyclodextrin; Base Peak [M+K+H]2+ CCS: 211 
Å2. E) Charge State 3+ from IM-MS Spectrum of Amino-β -Cyclodextrin; Base Peak 
[4M+3H]3+ CCS: 689 Å2. 
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Figure 5: A) IM-MS Spectrum of Hydroxypropyl-β -Cyclodextrin. B) MS Spectrum of 
Hydroxypropyl-β -Cyclodextrin; Base Peak [M+H]+ CCS: 298 Å2. C) Charge State 1+ 
from IM-MS Spectrum of Hydroxypropyl-β -Cyclodextrin; Base Peak [M+H]+ CCS: 298 
Å2. D) Charge State 2+ from IM-MS Spectrum of Hydroxypropyl-β -Cyclodextrin; Base 
Peak [M+K+H]2+ CCS: 460 Å2. E) Charge State 3+ from IM-MS Spectrum of 
Hydroxypropyl-β -Cyclodextrin; identifiable species unresolved. 
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Figure 6: A) IM-MS Spectrum of α-Cyclodextrin in negative mode. B) MS Spectrum of 
α-Cyclodextrin; Base Peak [M-H]-. C) Charge State 1- from IM-MS Spectrum of α-
Cyclodextrin; Base Peak [M-H]-. D) Charge State 2- from IM-MS Spectrum of α-
Cyclodextrin; Base Peak [3M-2H]2-. E) Charge State 3- from IM-MS Spectrum of α-
Cyclodextrin; Base Peak [8M-3H]3-. 
 
111011 ALPHA -VE 2.raw : 1










   
 
Figure 7: A) IM-MS Spectrum of β -Cyclodextrin in negative mode. B) MS Spectrum of 
α-Cyclodextrin; Base Peak [M-H]-. C) Charge State 1- from IM-MS Spectrum of β -
Cyclodextrin; Base Peak [M-H]-. D) Charge State 2- from IM-MS Spectrum of β -
Cyclodextrin; Base Peak [2M-2H]2-. E) Charge State 3- from IM-MS Spectrum of β -
Cyclodextrin; Base Peak [5M+K-4H]3-. 
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Figure 8: A) IM-MS Spectrum of ɣ -Cyclodextrin in negative mode. B) MS Spectrum of 
α-Cyclodextrin; Base Peak [M-H]-. C) Charge State 1- from IM-MS Spectrum of ɣ -
Cyclodextrin; Base Peak [M-H]-. D) Charge State 2- from IM-MS Spectrum of ɣ -
Cyclodextrin; Base Peak [2M-2H]2-. E) Charge State 3- from IM-MS Spectrum of ɣ -
Cyclodextrin; Base Peak [4M-3H]3-. 
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Figure 9: A) IM-MS Spectrum of Amino-β-Cyclodextrin in negative mode. B) MS 
Spectrum of α-Cyclodextrin; Base Peak [M-H]-. C) Charge State 1- from IM-MS 
Spectrum of Amino-β-Cyclodextrin; Base Peak [M-H]-. D) Charge State 2- from IM-MS 
Spectrum of Amino-β-Cyclodextrin; Base Peak [2M-2H]2-. E) Charge State 3- from IM-
MS Spectrum of Amino-β-Cyclodextrin; Base Peak [5M+K-4H]3- (*[3M-2H]2-). 
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Figure 10: A) IM-MS Spectrum of Hydroxypropyl-β-Cyclodextrin in negative mode. B) 
MS Spectrum of Hydroxypropyl -β -Cyclodextrin; Base Peak [M-H]-. C) Charge State 1- 
from IM-MS Spectrum of Hydroxypropyl -β-Cyclodextrin; Base Peak [M-H]-. D) Charge 
State 2- from IM-MS Spectrum of Hydroxypropyl -β-Cyclodextrin; Base Peak 
[2M+K+Na-4H]2-. E) Charge State 3- from IM-MS Spectrum of Hydroxypropyl -β-
Cyclodextrin; Base Peak [5M+K-4H]3-. 
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Figure 11) IM-MS Spectrum of Sphinganine without (A) and with (B) α-Cyclodextrin.  A) Arrow pointing out Sphinganine alone.  B) Arrow pointing out Sphinganine/ α -Cyclodextrin complex 
SA 72511 (25).raw : 1







Figure 12) IM-MS Spectrum of Sphingosine without (A) and with (B) α -Cyclodextrin.  A) Arrow pointing out Sphingosine alone.  B) Arrow pointing out sphingosine/ α -Cyclodextrin complex 
SO 72511 (25).raw : 1







Figure 13) IM-MS Spectrum of PMG without (A) and with (B) Alpha-Cyclodextrin.  A) Arrow pointing out PMG alone.  B) Arrow pointing out PMG/Alpha-Cyclodextrin complex 
SML 72511 (25).raw : 1







Table 1: Identified Species in IM-MS Spectrum of Alpha-Cyclodextrin (Positive Mode) 
 
Observed(m/z Identity CCS((Å2) Observed(m/z Identity CCS((Å2) Observed(m/z Identity CCS((Å2)
973.3710 M+H 226 506.1640 M+K+H 145 993.1070 3M+K+Na+H 368
995.3520 M+Na 227 984.3590 2M+Na+H 317 998.6620 3M+2K+H 372
1011.3320 M+K 229 992.3500 2M+K+H 314 1009.3190 3M+2K+MeOH2 372
1945.7680 2M+H 314 1000.3330 2M+Na+MeOH2 323 1322.7972 4M+2K+H 503
1967.7360 2M+Na 314 1478.5250 3M+K+H 417 1646.9200 5M+2K+H 598
1470.5410 3M+Na+H 435 1652.2590 5M+K+Na+MeOH2 591
1486.5300 3M+Na+MeOH2 437 1971.0700 6M+2K+H 679
1964.7150 4M+K+H 514 1976.3490 6M+K+Na+MeOH2 682






Table 2: Identified Species in IM-MS Spectrum of Beta-Cyclodextrin (Positive Mode) 
Observed(m/z Identity CCS((Å
2
) Observed(m/z Identity CCS((Å
2
) Observed(m/z Identity CCS((Å
2
)
1135.4810 M+H 244 587.2170 M+K+H 202 1155.4530 3M+K+Na+H 504
1157.4580 M+Na 255 1154.4580 2M+K+H 354 1160.7740 3M+2K+H 442
1173.4280 M+K 254 1146.4580 2M+H+Na 358 1538.9380 4M+2K+H 575
1721.7020 3M+K+H 474 1917.1090 5M+2K+H 690












) Observed(m/z Identity CCS((Å
2
) Observed(m/z Identity CCS((Å
2
)
1319.5580 M+Na 260 668.2560 M+K+H 230 1310.2290 3M+K+2H 487
1297.5640 M+H 260 660.2740 M+Na+H 244 1322.8610 3M+2K+H 493
1335.5370 M+K 267 1316.5460 2M+K+H 381 1749.7450 4M+K+Na+H 597
1297.5640 2M+2H 376 1742.4260 4M+K+2H 584






Table 4: Identified Species in IM-MS Spectrum of Amino-β-Cyclodextrin (Positive Mode) 
 
Observed(m/z Identity CCS((Å2) Observed(m/z Identity CCS((Å2) Observed(m/z Identity CCS((Å2)
1134.5100 M+H 252 586.7310 M+K+H 211 1889.8580 5M+3H 627
1156.4920 M+Na 255 578.7380 M+Na+H 208 1915.4640 5M+2K+H 642
1172.4560 M+K 256 605.7040 M+2K 213 2268.0380 6M+3H 689
2268.0380 2M+H 340 1134.5100 2M+2H 362 2275.0950 6M+Na+2H 695
1144.9650 2M+Na+H 354 2280.6820 6M+K+2H 714
1153.4790 2M+K+H 357 2645.8955 7M+3H 770








Table 5: Identified Species in IM-MS Spectrum of 2-Hydroxypropyl-β-Cyclodextrin (Positive  Mode) 
 
Observed(m/z Identity CCS((Å2) Observed(m/z Identity CCS((Å2)
1563.7974 M+Na 303 1552.7968 2M+Na+H 459
1579.7809 M+K 302 1560.7935 2M+K+H 460



























M:H 971.837 971.3961 2M:2H 1944.682 971.3824 7M:3H 6806.892 2267.9124
M+Cl 1008.298 1007.3691 2M+Na:3H 1965.656 982.3918 7M+Na:4H 6828.874 Not/Resolved
2M:H 1944.682 1943.792 2M+K:3H 1981.765 990.3665 7M+K:4H 6844.982 2280.6055
2M+Na:2H 1966.664 1965.7617 2M+K+Na:4H 1030.902 1001.372 8M:3H 7779.737 2592.1352
2M+Cl 1981.143 1979.7767 3M:2H 2916.520 1457.5961 8M+Na:4H 7801.719 Not/Resolved
3M+Na:3H 2961.491 1468.5789 8M+K:4H 7817.828 2604.7456
3M+K:3H 2954.610 1476.5615 9M:3H 8752.582 Not/Resolved
3M+K+Na:4H 2976.592 1487.5648 9M+Na:4H 8774.564 Not/Resolved





























M:H 1133.978 1133.4542 M:2H 1132.970 566.2231 5M+Na:4H 5693.888 1897.0618
M+Cl 1170.438 1169.4298 2M:2H 2267.956 1133.4542 5M+K:4H 5709.996 1902.3954
2M:H 2268.964 2267.9331 2M+Na:3H 1154.952 1144.4421 5M+K+Na:5H 5731.978 Not/Resolved
2M+Na:2H 2290.946 2289.9918 2M+K:3H 2306.046 1152.4248 5M+2K:5H 5748.087 1915.0927
2M+Cl 2305.424 2303.9158 3M:2H 3402.942 1700.6729 6M:3H 6806.892 2267.9124
3M+Na:3H 3424.924 1711.6665 6M+Na:4H 6828.874 Not/Resolved
3M+K:3H 3441.032 1719.6495 6M+K:4H 6844.982 Not/Resolved
4M:2H 4537.928 2267.9331 6M+K+Na:5H 6866.964 Not/Resolved























M:H 1296.119 1295.5515 M:2H 1295.111 647.2702 4M:3H 5185.484 1727.7138
M+Cl 1332.579 1331.5212 2M:2H 2592.238 1295.5515 4M+Na:4H 5207.465 1735.0522
2M:H 2593.246 2592.1353 2M+Na:3H 2630.328 1306.5228 4M+K:4H 5223.574 1740.3901
2M+Cl:H 2628.698 1313.5460 5M:3H 6482.610 2159.9382
3M:2H 3889.365 2592.1353 5M+Na:4H 6504.592 Not/Resolved
3M+Na:3H 3911.347 2603.1172 5M+K:4H 6520.701 2172.2646
3M+K:3H 3927.455 2610.6155 6M:3H 7779.737 Not/Resolved























M:H 1132.9933 1132.4833 2M+Na:3H 2287.9685 1143.4813 4M+K:4H 4571.0715 1522.9849
M+Cl 1169.4537 1168.4586 2M+K:3H 2304.0770 1151.4608 5M:3H 5666.9823 1888.1448
2M:H 2266.9945 2265.9771 2M+2K+Na:5H 2364.1493 1181.4766 5M+Na:4H 5688.9642 1895.4631
2M+Na:2H 2289.9843 2287.9790 2M:2H 2265.9866 1132.4833 5M+K:4H 5850.9143 1900.4897
2M+Cl 2303.4549 2301.9863 3M+Na:3H 3421.9697 1710.2203 5M+K+Na:5H 5737.1336 Not/Resolved
3M+2K+Na:5H 3498.1505 1748.2205 5M+2K:5H 5743.1631 Not/Resolved
3M+Cl:H 3436.4482 1717.2218 5M+2K+Na:6H 5765.1450 Not/Resolved
3M:2H 3399.9878 1699.2313 6M:3H 6807.0309 Not/Resolved
4M:2H 4533.9890 2265.998 6M+Na:4H 6822.9654 Not/Resolved
4M+Na:3h 4555.9709 2276.9751 6M+K:4H 6839.0739 Not/Resolved
4M+2K+Na:5H 4632.1517 2314.9004 6M+K+Na:5H 6861.0558 Not/Resolved
4M+Cl:H 4570.4494 2283.967 6M+2K+Na:6H 6899.1462 Not/Resolved




















M<H 1482.454 1481.7384 M<2H 1481.446 740.3687
M+Cl 1518.914 1517.7024 2M<2H 2964.907 1481.7374



























25V CCS 0.55 1.07
All data acquired on 7/25/11 except where noted
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